Inactive Instrument

Xynomic Pharmaceuticals Holdings, Inc.

XYN

US98421X1028

Xynomic Pharma Appoints Dr. Sophia Paspal as the Vice President, Regulatory Affairs and Quality Assurance

February 27, 2019 at 01:01 pm

Xynomic Pharma appointed Dr. Sophia Paspal as the Vice President, Regulatory Affairs and Quality Assurance. Dr. Paspal assumes overall responsibility to strengthen Xynomic’s regulatory compliance and quality assurance functions. Dr. Paspal brings 20 years of relevant global industry experience. From 2017 to January 2019, Dr. Paspal worked at Capricor Therapeutics, Inc. and Cellics Therapeutics, Inc., holding the same title.

Latest news about Xynomic Pharmaceuticals Holdings, Inc.

Xu-Nuo Pharma, Inc. acquired the remaining 2% stake in Xynomic Pharmaceuticals Holdings, Inc..	16/06/21	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Resignation of Richard Peidong Wu as Independent Director and the Chairman of the Audit Committee	29/06/20	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	01/06/20	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/11/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma	23/09/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Management Changes	20/09/19	CI
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial	13/09/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda in Multiple Solid Tumors	30/08/19	CI
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors	16/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	15/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Approves Application to Conduct Pivotal Phase 3 Trial Using Abexinostat	07/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Files Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA	01/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives China Approval to Start 2 Pivotal Lymphoma Clinical Trials	30/07/19	CI
Xynomic Pharmaceuticals Holdings, Inc. announced that it expects to receive $14.999998 million in funding	09/07/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Board Changes	05/07/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Completes Pre-IND Meeting with US FDA for XP-102	12/06/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Doses First Patient in Phase 1/2 Lymphoma Trial	06/06/19	CI
Xynomic Pharmaceuticals Holdings, Inc.(NasdaqCM:XYN) added to NASDAQ Composite Index	15/05/19	CI
Xynomic Pharmaceuticals, Inc completed the acquisition of Bison Capital Acquisition Corp. in a reverse merger transaction.	14/05/19	CI
Xynomic Pharmaceuticals, Inc Appoints Jinwei Coco Kou as the Interim Chief Accounting Officer	20/03/19	CI
China, Spain and Poland Authorities Approves Xynomic Pharmaceuticals, Inc.'s Application	16/03/19	CI
Xynomic Pharma Appoints Dr. Sophia Paspal as the Vice President, Regulatory Affairs and Quality Assurance	27/02/19	CI
Xynomic Pharma Will Present at ASCO-GU Cancers Symposium, Files 3 INDs for Potentially Pivotal Cancer Trials in China, and Expands R&D Operations	27/12/18	CI
Xynomic Pharmaceuticals, Inc entered into a non-binding letter of intent to acquire Bison Capital Acquisition Corp. in a reverse merger transaction.	11/09/18	CI
Xynomic Pharmaceuticals, Inc. announced that it has received funding from Northern Light Venture Capital, Hakim Unique Internet Co., Ltd., Shanghai Prosperico Ventures Co., Ltd., and other investors	31/05/18	CI

Chart Xynomic Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Xynomic Pharmaceuticals Holdings, Inc.

More charts

Company Profile

XYNOMIC PHARMACEUTICALS HOLDINGS, INC. is a China-based biopharmaceutical company. The Company, together with its subsidiaries, are principally engaged in in-licensing, developing and commercializing oncology drug candidates in the People's Republic of China (PRC), the United States, and rest of the world. To date, the Company has not yet generated any revenue from product sales.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-1.56%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.49B
BIOGEN INC.	-12.97%	32.79B
UCB	+61.72%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.52B
INCYTE CORPORATION	-7.31%	13.09B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.6B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.82B

Biopharmaceuticals